Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) - Total Liabilities
Latest total liabilities as of September 2025: CN¥3.56 Billion CNY
Based on the latest financial reports, Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has total liabilities worth CN¥3.56 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Total Liabilities Trend (2013–2024)
This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Sinopep-Allsino Biopharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhengzhou GL Tech Co Ltd
SHE:300480
|
China | CN¥641.74 Million |
|
Jiangsu Shentong Valve Co Ltd
SHE:002438
|
China | CN¥2.36 Billion |
|
Banca IFIS S.p.A.
LSE:0NBX
|
UK | €11.19 Billion |
|
Tansun Technology Co Ltd
SHE:300872
|
China | CN¥730.71 Million |
|
Global Power Synergy Public Company Limited
BK:GPSC-R
|
Thailand | ฿163.40 Billion |
|
Yantai China Pet Foods Co Ltd
SHE:002891
|
China | CN¥2.26 Billion |
|
KPC Pharmaceuticals Inc
SHG:600422
|
China | CN¥5.15 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2024)
The table below shows the annual total liabilities of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.40 Billion | +76.42% |
| 2023-12-31 | CN¥1.36 Billion | +127.30% |
| 2022-12-31 | CN¥597.41 Million | +87.78% |
| 2021-12-31 | CN¥318.14 Million | -25.94% |
| 2020-12-31 | CN¥429.55 Million | +5.92% |
| 2019-12-31 | CN¥405.54 Million | +52.76% |
| 2018-12-31 | CN¥265.47 Million | -8.55% |
| 2017-12-31 | CN¥290.27 Million | +131.92% |
| 2016-12-31 | CN¥125.16 Million | +1.46% |
| 2015-12-31 | CN¥123.35 Million | -28.72% |
| 2014-12-31 | CN¥173.05 Million | +6.09% |
| 2013-12-31 | CN¥163.12 Million | -- |